Medartis Holding AG (MED – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dylan Van Haaften from Stifel Nicolaus maintained a Buy rating on the stock and has a CHF86.00 price target.
Dylan Van Haaften has given his Buy rating due to a combination of factors that highlight Medartis Holding AG’s potential for growth. The company has shown strong performance in the EMEA region, particularly with the success of the Keri TOUCH prosthesis and the distal radius plate, which have driven revenue growth across key geographies such as Germany, Austria, and the UK. Additionally, the US market is undergoing a strategic review, with promising developments like the acquisition of In2Bones Global, Inc., which is expected to enhance Medartis’s presence in the Upper Extremities joint replacement market.
Despite a conservative FY25 guidance that is below consensus, Medartis is expected to maintain a high-teen EBITDA margin, indicating resilience in profitability. The company’s strategic moves, including the acquisition of a stake in NeoOrtho in Brazil, suggest a multi-tiered product approach that could mirror successful strategies seen in other markets. Furthermore, the new CEO’s initiatives and the upcoming strategy presentations are anticipated to provide a clearer medium-term growth trajectory, which could positively influence investor sentiment.
According to TipRanks, Van Haaften is ranked #7302 out of 9384 analysts.